Praful Ravi, MB, BChir, MRCP

home / authors / praful-ravi-mb-bchir-mrcp

Articles

Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.

Monitoring Response to Radioligand Therapy in Prostate Cancer

Praful Ravi, MB, BChir, MRCP
October 2nd 2025

Biochemical markers and advanced imaging modalities play a critical role in monitoring patients undergoing RLT therapy for metastatic prostate cancer.

Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.

Fitting Radioligands Into the Metastatic Prostate Cancer Treatment Paradigm

Praful Ravi, MB, BChir, MRCP
October 1st 2025

Data support the use of radioligand therapy in combination with androgen receptor pathway inhibitors to optimize prostate cancer outcomes.

“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.

Breaking Down the Phase 2 LASER trial of 177Lu-PSMA-617 in Clear Cell RCC

Praful Ravi, MB, BChir, MRCP
July 26th 2025

“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Praful Ravi, MB, BChir, MRCP, on the phase 2 LASER trial in RCC.

Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.

177Lu-PSMA-617 Trial May Be Efficacious in Advanced PSMA-Expressing ccRCC

Praful Ravi, MB, BChir, MRCP
July 25th 2025

Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.

Latest Updated Articles

Treosulfan plus fludarabine is now approved by the FDA as an injection for allo-HSCT conditioning for patients with AML or MDS.
Published: January 24th 2025 | Updated: February 6th 2025
FDA Approves Treosulfan Combo Injection for HSCT Conditioning in AML/MDS
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
Published: September 13th 2024 | Updated: November 25th 2024
Non–clear Cell RCC: First-Line Treatment Options and Guideline Updates
NSABP B-42 trial results show that the assay was predictive of extended letrozole therapy response, identifying a patient subset with improved outcomes.
Published: August 9th 2024 | Updated: August 14th 2024
Gene Assay May Predict Extended Letrozole Benefits in Breast Cancer Subsets
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Published: June 2nd 2024 | Updated: June 3rd 2024
OS Prolonged With Perioperative Chemo Vs Neoadjuvant CRT in Esophageal Cancer
Data from the CheckMate-67T trial support the biologics license application for subcutaneous nivolumab in multiple solid tumors.
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab in Solid Tumor Indications
SAR-bisPSMA is a targeted copper theranostic that can be used for either imaging or therapy, depending on which copper isotope is paired with it.
Published: October 15th 2025 | Updated: October 23rd 2025
64Cu-SAR-bisPSMA PET Detects More Prostate Cancer Lesions vs SOC